



Tuesday, 16 June 2009

PRESS RELEASE

GREAT WESTERN HOSPITAL SWINDON, ADOPTS L-DEX™ FOR PRE-EMPTIVE CARE IN BREAST CANCER PATIENTS TO HELP PREVENT LYMPHOEDEMA.

Another leading NHS institution has adopted ImpediMed's L-Dex U400 device to improve existing lymphoedema care and to continue their efforts in striving for excellence in overall patient care.

"The Breast Cancer Team at Great Western Hospital (GWH), Swindon, is committed to delivering the best possible care to our breast cancer patients. At GWH we intend to use the L-Dex technology to assess breast cancer patients for fluid retention of the arm (lymphoedema) from pre-surgical baselines. This pre-emptive strategy allows the opportunity for early assessment of the disorder. In this way we hope to audit the outcome for our breast cancer patients at GWH and deliver a timely response and intervention to any early detection of lymphoedema," said Consultant General, Breast and Endocrine Surgeon Dr. Nathan Coombs.

"The UK was one of the first socialised health systems to bring through lymphoedema guidelines – the 'Northern Ireland CREST guidelines'¹. This clear recognition of lymphoedema as a major healthcare issue and the commitment to improve lymphoedema services is representative of the pro-active nature of healthcare professionals at every level working within the UK healthcare system. It is encouraging to see the focus applied to the early assessment and possible prevention of the progression of this debilitating disorder."

"ImpediMed is heartened to see the growing recognition and willingness to include lymphoedema care from day one for all breast cancer patients. Education and awareness are critical to the overall prevention strategy of this disorder and ImpediMed will strive to ensure medical devices are available to aid in the early clinical assessment of patients," commented Greg Brown, CEO of ImpediMed.

ENDS

For further information contact:

Greg Brown Impedimed CEO +61-7-3860-3700

1. CREST. Guidelines for the Diagnosis, Assessment and Monitoring of Lymphoedema. February, 2008. ISBN 978-1-903982-32-7

L-Dex™ is a trademark of ImpediMed Limited.

“ L-Dex™ values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.